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Objectives: Age-related changes mean that the older population can encounter barriers toward taking
medication orally. Further work is needed to identify the characteristics of oral solid dosage forms that
will improve patient acceptance and adherence. The aim of this systematic review was to identify if and
how formulation aspects of oral solid dosage forms affect acceptance and adherence in older people.
Design: Mixed methods systematic review using a data-based convergent synthesis design.
Setting and Participants: Articles were selected if they included participants aged 60 years and older, or
included health care professionals, social care professionals, and informal carers of patients aged 60 years
and older.
Methods: A systematic search of the following databases was undertaken: Web of Science, MEDLINE,
Scopus, and The Cochrane Databases. The search of databases was supplemented by a search of gray
literature, and reference lists of included papers were manually searched.
Results: A total of 16 studies were included in the final synthesis. Three themes were generated from the
thematic analysis: (1) dimensions, (2) palatability, and (3) appearance. The dimensions and palatability
are often modified to improve swallowability by breaking tablets in half or taste masking with food.
Polypharmacy can lead to patients using the appearance to identify tablets; however, this can lead to
confusion when products appear similar. No study was identified that explored formulation character-
istics across all 3 categories directly in the older population.
Conclusion and Implications: Manufacturers should take into account practical problems older people
may encounter when considering the dimensions, palatability, and appearance of the final drug product.
These characteristics should be optimized to aid visual identification and swallowability. Medical pro-
viders and pharmacists have an important role in ensuring that these patient-centric drug products are
prescribed and dispensed appropriately so that patients receive the most suitable formulation.
 2020 AMDAd The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).3Optimizing the use of medication requires a patient-centered
approach to provide the best possible outcomes.1 Comorbidities, in
addition to changes in cognitive, motor, and sensory functions, must
be considered to prevent practical medication difficulties in older
people.2 These comorbidities include conditions that predispose older
adults toward dysphagia, such as neurologic disorders andn Limited, Dartford, Kent, and
rm, School of Life and Health
d Kingdom.
).
e and Long-Term Care Medicine. Thgastroesophageal disease. Complications arising from gastroesopha-
geal disease, including esophageal stricture and cancer, are more
common in older people and can lead to further problems adminis-
tering medication orally.4 Although most causes of dysphagia are due
to a structural cause or organic disease, many patients without a
clinical diagnosis of dysphagia also report difficulties due to an aver-
sion to swallowing medication.5
EuropeanMedicines Agency and US Food and Drug Administration
guidance suggest the use of a wider range of colors, sizes, and shapes
to help patients recognize their medication, reduce the potential for
medication errors, and aid swallowability.6,7 However, a primary focus
is often placed on the safety, efficacy, and quality of a new drug
product that can lead to practical issues being commonly overlooked.8is is an open access article under the CC BY-NC-ND license (http://creativecommons.
Z.B. Shariff et al. / JAMDA xxx (2020) 1e92Dosage forms are routinely modified,9 and this can result in patient
harm, especially when crushing and opening capsules are contra-
indicated for some preparations.10 Taking into account age-related
changes in the design and development of medication will help to
ensure that the end product can be used by a patient group in a safe
and efficacious manner.11
This mixed methods systematic review, therefore, aims to identify
both quantitative and qualitative studies that investigate if and how
the formulation of oral solid dosage forms affects acceptance and
adherence in older people. Formulation has been defined as “a dosage
form with a particular composition and with specific product char-
acteristics, eg, tablet size, shape, colour, embossing, and break mark.”2Methods
The review was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(Supplementary Table 1), and the protocol was registered on PROS-
PERO (registration no. CRD42018088969).
A systematic search of the following databases from inception to
May 2019 was undertaken: Cochrane Central Register of Controlled
Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR),
MEDLINE, Scopus, and Web of Science. No language or time re-
strictions were placed on the initial search. Search terms included a
combination of Medical Subject Heading terms and a comprehensive
list of synonyms relating to (1) formulation factors, (2) oral solid
dosage forms, (3) patient adherence, and (4) older patients
(Supplementary Table 2).
The database search was supplemented by a gray literature search.
The reference lists of included studies and reviews were manually
checked, and reviews were then excluded from the final list of
included studies. The gray literature search was further supplemented
by checking a minimum of the first 100 hits on Google Scholar and
continuing until 10 or more consecutive irrelevant hits were retrieved.
Included studies met the following criteria: (1) included older
people aged 60 years and older (studies including patients aged
<60 years were included and relevant data extracted) or included
health care professionals, social care professionals, and informal carers
of patients aged 60 years and older; (2) investigated the formulation of
oral solid dosage forms (as defined by the European Medicines
Agency2); (3)measured patient adherence or acceptance, either directly
or indirectly; and (4) the full text was available in English.
An initial title screen identified titles that were clearly not relevant
(Z.S.). Titles and abstracts were then screened independently by the
reviewers (Z.S., D.D.), after which the full texts of potentially eligible
studies were retrieved and also independently assessed. Disagree-
ments were resolved by consulting a further team member (I.M.).
Study quality was independently assessed by 2 reviewers (Z.S., D.D.)
using the Mixed Methods Appraisal Tool (MMAT), version 2018.12
Studies were categorized into study design and assessed based on
methodology used. The tool was adapted to include a column stating
whether studies were sponsored by the pharmaceutical industry.
Data were entered onto a standardized spreadsheet. Two review
authors (Z.S., D.D.) extracted data independently, and any discrep-
ancies were identified and resolved through discussion with a third
author (I.M.). Using the European Medicines Agency definition of
formulation,2 data relating to the formulation characteristic(s)
explored in each study were also extracted and tabulated.
Findings from both qualitative and quantitative studies were inte-
grated using a data-based convergent synthesis design.13 This approach
involves data transformation so that all studies are analyzed using the
samesynthesismethod.13 The thematic synthesis approach, asdiscussed
by Thomas and Harden,14 was then used to synthesize all findings.Results
Review Process
Supplementary Figure 1 summarizes the review process; 77 arti-
cles were included at full text, of which 14 met the inclusion criteria
(see Supplementary Table 3 for reasons for exclusion). Two additional
articles were identified from reference searching.
Characteristics of Included Studies
The characteristics of the included studies are summarized in
Table 1. Eight studies were conducted in patients older than 60 years
exclusively.15e22 Relevant data were extracted from the remainder.
One study involved physicians as well as patients.23 The formulation
of oral solid dosage forms, as defined for the review, was explored
directly by 10 of the 16 studies.16,19e22,24e28 The remaining 6 studies
investigated formulation indirectly, with a primary focus on generic
substitution, general medication-taking practices, and swallowing
difficulties.15,17,18,23,29,30 The formulation characteristic(s) explored
can be found in Table 2.
Quality Appraisal
The results from the quality appraisal are shown in Supplementary
Table 4. All studies were included in the final synthesis with greater
emphasis placed on higher quality studies.
Analytical Themes
Three themes were generated from the thematic analysis of data:
(1) dimensions, (2) palatability, and (3) appearance.
Dimensions
Studies that investigated formulation indirectly in older people
illustrated the importance of size, with 29.6% of use difficulties (sit-
uations where the participant can only complete a task with difficulty)
attributed to the dosage form being too large or small.18 In general,
there was a preference for smaller dosage forms; “tablet size was too
big” was the most common cause of ongoing and past swallowing
difficulties in patients with dysphagia.30 However, tablets that were
too small led to difficulties handling the tablet and locating the
product in the mouth.18 Preferences for size were also often depen-
dent on shape, because of the ease of swallowing dosage forms with a
minimum cross-sectional area.23 Little more than 40% of older people
with dysphagia selected the 11-mm arched round tablet as having the
potential to cause difficulties, compared with approximately 35%
selecting the 13-mm oblong tablet.16
The presence of dysphagia influenced the findings: 40% of older
people without dysphagia reported having no difficulties swallowing
any of the capsule sizes presented, compared with only 6% with
dysphagia.16 Specifically, sizes of 11 and 13 mm were found to start
causing difficulties in older people with dysphagia.16 Patients with
swallowing difficulties thereforemodified dosage formsmore often;22
that is, 80% of patients with swallowing difficulties modified the
dosage form compared with 19% of patients without.22
The presence of dysphagia was also found to influence preferences
for shape. Two studies found that the older population reported fewer
swallowing difficulties than younger people,23,25 and one of these
went on to state that of patients who were not affected by swallowing
difficulties, 69.7% did not care about tablet shape.23 This is supported
by a further study conducted exclusively in older people, which found
that older people without dysphagia had fewer preferences for a
Table 1
Characteristics of Included Studies (Listed Alphabetically According to First Author)
Reference Country Aim Study Design Sample Size and Age Data Collection Methods Data Analysis Methods
den Uyl et al24 Netherlands To compare the preference and
acceptability of 2 calcium plus
vitamin D-3 formulations
Quantitative randomized,
open, cross-over
clinical trial
102 patients visiting an
outpatient clinic aged
between 34 and 83 y. Mean
age 66 y
Acceptability questionnaire and
overall preference
assessment
A logistic regression model was
used to analyze the difference
between the 2 formulations
and provide an estimate of
the sequence effect. A linear
mixed model was used to
analyze the secondary
efficacy end points
Heikkilä et al29 Finland To explore the factors that
influence the choice of
medication following the
introduction of generic
substitution (GS)
Population-based survey 1844 people divided among 18-
59-y-olds (61%) and 60-94-y-
olds (39%)
Questionnaire consisting of
structured and open-ended
questions
SPSS 17.0.1 statistical software
using frequencies and cross-
tabulations for descriptive
analysis
Hofmanová et al25 United Kingdom To investigate the oral sensory
properties and swallowability
of coated placebo tablets
Quantitative randomized
double-blind study
Nonsmoking healthy adults
aged 18-75 y; those aged
>55 y were targeted and
made up 50.6% of the overall
population
Background questionnaire and
tablet sample assessment
using visual analog scales
A number of statistical analyses
conducted using SPSS, version
24, to explore the differences
between each of the tablet
samples and to explore the
impact of patient
demographics on responses
Jones et al26 United States To compare the preference of
softgel capsules vs
conventional solid dosage
forms
Quantitative
descriptive study
300 consumers evenly divided
among the age groups of 25-
39 y (31%), 40-59 y (33%), and
60þ y (36%)
Consumer preference survey Exact analysis methods not
stated
Kelly et al15 England To explore the experiences of
taking medication for older
people with dysphagia
Qualitative study with
semistructured
face-to-face
interviews
11 patients who had different
degrees of dysphagia over the
age of 60 y
Semistructured interviews Content analysis to generate
themes that were then
integrated so that they could
be related back to the
research question
Liu et al16 England To assess the acceptability of a
range of oral solid dosage
forms (OSDFs) in older
ambulatory patients
Quantitative
descriptive study
156 patients taking at least 1
oral solid medicine older than
65 y
Sydney Swallow Questionnaire
(assessing swallowing
function); pilot of the
Medicines Acceptability
Questionnaire; patients
shown samples of OSDFs
Data analysis was performed
using the Statistical Package
of the Social Sciences (SPSS)
version 22.0
Marquis et al30 Two Swiss
regions: Basel
and Lausanne
To determine the prevalence of
swallowing difficulties, the
strategies to overcome these
and health professionals’
awareness of these problems
Quantitative
descriptive study
410 enrolled patients aged
18 y (mean age 66.5 y)
taking at least 3 different oral
solid dosage forms
Interview combining closed-
ended, open-ended, and
Likert-scale items
Data analysis was performed
using the Statistical Package
of the Social Sciences (SPSS)
version 15.0
Notenboom et al17 Netherlands To identify the practical
problems that older people
experience with the daily use
of their medicines
Qualitative study
with semistructured
face-to-face interviews
59 community-dwelling people
aged 70 y (mean age 78.4 y)
Semistructured interviews Transcribed data were coded
independently. Each practical
problem/management
strategy was classified on a 3-
point scale according to the
level of discomfort and
clinical deterioration likely to
result
Notenboom et al18 Netherlands To identify design features of
oral medicines that cause use
problems among older
patients
Qualitative study with
semistructured
interviews
59 community-dwelling people
aged 70 y (mean age 78.4 y)
Semistructured interviews Transcribed data were coded
independently. Each practical
problem and management
strategy was categorized as a
“use difficulty” or a “use
error”
(continued on next page)
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Table 1 (continued )
Reference Country Aim Study Design Sample Size and Age Data Collection Methods Data Analysis Methods
Phillips et al19 United Kingdom To compare the ease of
swallowing a single oral dose
of a standard tablet of
acyclovir vs a film-coated
tablet
Quantitative
randomized
crossover study
104 volunteers from the
department of medicine for
older adults at Orpington
Hospital aged 71-94 y (mean
age 82 y)
Patients asked to swallow 1
formulation and then
24 hours later received a
second formulation;
preference assessed
Tabulation detailing the
number and percentage of
patients who preferred the
standard formulation, the
coated formulation and who
expressed no preference
Rees and Howe20 United Kingdom To compare the acceptability
and preference of 2 chewable
preparations of calcium and
vitamin D: Calcichew D3 Forte
(CDF) and Ad Cal D3 (ACD)
Quantitative
randomized,
investigator-blind,
crossover,
multicenter study
94 patients aged 60 y (mean
age 72.6 y)
Visual analog scales (VASs) used
to assess acceptability; overall
preference assessment
The distribution of the VAS
scores were tested using the
Shapiro- Wilk test and
univariate summary statistics.
Data were log transformed
before applying an analysis of
variance for a 2-period
crossover design.
Reginster et al27 Belgium To compare the preference for
and acceptability of 2
formulations containing
calcium and vitamin D
Quantitative randomized,
open-label crossover trial
199 patients were included in
the intent-to-treat analysis;
preference data were
available for 178 patientsdall
aged 18 y (mean age 66 y)
Acceptability questionnaire and
overall preference
assessment
A logistic regression model was
used to analyze the difference
between the 2 formulations
and provide an estimate of
the sequence effect. A linear
mixed model was used to
analyze the secondary
efficacy end points. SAS,
version 8.2, was used in all
statistical analyses.
Rodenhuis et al28 Netherlands To measure patient satisfaction
with score lines on tablets
Quantitative descriptive study 140 patients with prescriptions
for scored tablets that
had to be broken (50% of
prescriptions broken by
60-y-olds)
Survey conducted by
pharmacies to explore patient
experiences with the
functioning of the score line
Tabulation analyzing the
prescriptions for scored
tablets by age of breaker,
negative evaluation, and type
of negative evaluation. Data
were also analyzed to explore
negative evaluations of
specific drugs and actions
taken by the patient on
negative evaluation.
Schiele et al23 Germany To assess the prevalence of
difficulties in swallowing oral
solid dosage forms in a
general practice population
and to explore the reasons,
nature, and characteristics of
tablets and capsules causing
these difficulties
Quantitative descriptive study 1051 patients taking at least 1
oral solid dosage form aged
18 y (mean age of those
completing the medication
list 62.7 y); 16 general
practitioners (GPs)
Two structured questionnaires;
GPs completed a separate
questionnaire to predict
swallowing difficulties
For the main questionnaire, a
statistical analysis was
conducted using the SAS
statistical software package.
Data from themedication lists
were matched to a drug
database. Medication
characteristics such as the
width, height, and diameter
were analyzed in relation to
any associations with
swallowing difficulties.
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Z.B. Shariff et al. / JAMDA xxx (2020) 1e9 5particular shape.16 In contrast, older people with dysphagia had a
preference for “torpedo”-shaped tablets or capsules.15
Break marks are sometimes used to provide a means of over-
coming challenges associated with larger tablets by allowing them to
be broken into 2 halves that are swallowed separately. More often, a
break mark enables dose flexibility by allowing half doses to be pre-
scribed. However, neither purpose currently works well for older
people who experience difficulties when the break mark does not
function well, leading to use errors.18 These include tablets breaking
into unequal portions or crumbling and unintended breaking of the
tablet.18 Management techniques, including taking unequal halves,
had the potential to cause severe discomfort or clinical deterioration.17
These findings were supported by a further study investigating patient
experiences with the performance of tablet score lines:28 a total of 24
of 51 negative evaluations of the score line were reported in patients
aged 60 years and older.28
Palatability
Texture, mouthfeel, and coating
Surface texture was the second most commonly reported cause
(relating to the dosage form) of swallowing difficulties in people with
dysphagia, with 70.5% of participants identifying a problem with this
feature.23 Surface characteristics further contributed to 18.5% of use
difficulties in older people.18 Participants used the term “chalky” to
describe the texture of tablets that were difficult to take.15 “Chalki-
ness” was also a variable that was directly measured to assess the
acceptability of chewable formulations using the visual analog scale,
and the results indicate an overall preference toward “not chalky at
all” chewable formulations.20
The coating of the formulation is also important in determining the
texture and mouthfeel, and further affects swallowability. In 1 study,
11 of 16 occasions when the medication became stuck in the mouth or
throat occurred with uncoated tablets.18 Of those who expressed a
preference, 79% of older people preferred the coated tablet over the
uncoated tablet.19 Furthermore, patients taking uncoated tablets were
found to require more water to swallow the tablet, took longer to
swallow, and reported a higher incidence of the tablet being lodged
within the esophagus.25
The nature of the coating, in addition to the presence of a coating,
is important in determining acceptability and is evaluated on
smoothness, stickiness, slipperiness, and palatability.25 Paracetamol
formulations that often have a “rugged coating”were most commonly
reported as being the most difficult to swallow.30 Furthermore, a
“sticky coating”was reported to be the second most common cause of
ongoing and past swallowing difficulties.30
Taste
Taste was significant in predicting the acceptability of an alen-
dronic acid tablet formulation using the Medicine Acceptability
Questionnaire.21 Some active pharmaceutical ingredients, such as
ferrous fumarate, have an inherently bitter taste and require taste
masking with food.17 The need for taste masking increased when
medications were crushed; various substances such as milk, apple
juice, bread, tea, and fruit smoothies were used to mask the “horrible”
taste.15 Further studies found that in 19% (205) of 1079 evaluations,
older people used food or drink just before or after administration to
mask the taste or to improve ease of swallowing.22
Chewable tablets and granules are commonly used for people with
swallowing difficulties; however, the taste is significantly more
important for these formulations, as they spend longer in the oral
cavity. Taste was, therefore, consistently measured as a variable that
would impact overall acceptability.20,24,27 Although the taste of the
chewable tablet was preferred to that of granules, comparing scores
for all 5 acceptability variables (including taking the dose, time spent
Table 2
Findings in Relation to Formulation Characteristics
Author Oral Solid Dosage Form Formulation
Characteristic
Key Findings % Patients
Aged 65 y
% Patients
Aged 60 y
Mean
Age, y
den Uyl et al24 Chewable tablets and sachets Taste The mean acceptability score for taste was
higher for the tablet than for the powder.
There was an overall significant preference for
the chewable tablet.
59.4 66
Heikkilä et al29 Tablets and capsules Shape
Color
“Splittability”
External characteristics including the shape and
color were less significant than the familiarity
of a medication, especially for older people.
39 54
Hofmanová et al25 Tablets Coating
Roughness
Stickiness
Slipperiness
Palatability
Older people were able to distinguish between
a coated and uncoated tablet. Coated tablets
were more acceptable, and stickiness and
roughness were most strongly linked to tablet
acceptance. Palatability was not found to be
associated with acceptability.
38.6 N/A
Jones et al26 Softgels, compressed tablets,
gelatin-coated tablets,
hard-shell capsules
Shape The clear oval softgel was preferred most often,
followed by the clear oblong softgel. The
round compressed tablet was the least
preferred.
36 N/A
Kelly et al15 Tablets and capsules Shape
Size
Coating
Texture
Taste
Torpedo-shaped tablets or capsules were
preferred.
Small tablets were generally easier to swallow;
however, small round tablets were also
troublesome.
A smooth coating was preferred.
A “chalky” texture was described as
troublesome.
Taste was not a major issue unless tablets were
crushed.
100 N/A
Liu et al16 Tablets, hard gelatin
capsules, minitablets,
granules, dispersible tablets,
ODTs, chewable tablets
Size
Shape
Taste
Appearance
Sizes of 11 mm and 13 mm started to cause
difficulties swallowing.
Mini tablets (4-mm) were considered easier to
swallow; however, concerns were raised in
relation to seeing and handling.
Oval and oblong shapes were considered
slightly easier to swallow than flat, round, and
arched.
There were concerns on taste for all dosage
forms (apart from tablets and capsules).
There were concerns on the appearance of
granules.
100 74.0
Marquis et al30 Tablets, effervescent tablets,
chewable tablets,
powders, granules
Size
Coating
Taste
Shape
Size was the most commonly reported cause of
swallowing difficultiesd63% of people with
past or ongoing swallowing difficulties said
size was the main cause.
Coating was the second most commonly
reported cause of swallowing difficulties, with
29.3% reporting difficulties with a “sticky
tablet.”
10.9% of those with past or ongoing difficulties
said the “bad taste or smell” of the tablet was
the cause of this. The main drawback of
powders and granules was their taste.
Shape was not mentioned as a trigger of
swallowing difficulties.
66.5
Notenboom et al17 Tablets, dispersible tablets Appearance
Break marks
Size
Taste
Difficulties distinguishing between different
strengths due to similarities in appearance led
to discomfort and clinical deterioration.
Breaking of tablets were reported as difficult or
painful.
60.7% of problems relating to the taking of
medicines were caused by the medicines
lodging in the mouth or throat.
35% of problems relating to the taking of
medicines were caused by the flavor of
medicines, including ferrous fumarate.
100 78.4
(continued on next page)
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Table 2 (continued )
Author Oral Solid Dosage Form Formulation
Characteristic
Key Findings % Patients
Aged 65 y
% Patients
Aged 60 y
Mean
Age, y
Notenboom et al18 Tablets, dispersible tablets Dimensions
Surface texture
Appearance
Break mark
Taste
29.6% of use difficulties were due to the
dimensions of the dosage form, including
problems holding the medicine and problems
swallowing.
18.5% of use difficulties were due to the surface
texture, which led to problems swallowing
and medicines getting stuck in the throat. Of
the 16 medicines that got stuck in the throat,
11 were uncoated tablets.
3 use difficulties and 7 use errors were the
result of the appearance of oral solid dosage
forms (OSDFs), which led to difficulties
distinguishing between tablets.
3 use difficulties and 5 use errors were due to
break marks not functioning well.
6 use difficulties and 4 use errors were due to
the unpleasant taste.
100 78.4
Phillips et al19 Tablets Coating 50% of patients reported no preference for a
coated or uncoated formulation. Of those who
expressed a preference, 79% preferred the
film-coated tablet, the main reasons being
that it was “smoother” and “easier to
swallow.”
100 82
Rees and Howe20 Chewable tablets Taste
Chewiness
Grittiness
Chalkiness
Ease of swallowing
Stickiness
Two high-dose preparations of calcium and
vitamin D were compared: Calcichew D3
Forte (CDF) and Ad Cal D3 (ACD). Although
these were similar in terms of dose and active
constituents, there was a statistically
significant difference in all scores except taste,
indicating one formulation (CDF) was more
acceptable than the other (ACD); overall,
79.8% of patients stated a preference for CDF,
10.6% preferred ACD, and 9.6% had no
preference.
100 72.6
Reginster et al27 Chewable tablets and sachets Taste Mean acceptability score was higher for the
tablet than for the powder; however, taste
scored the lowest overall acceptability score
out of all 5 acceptability variables. An overall
significant preference was observed for the
chewable tablet; 73.3% of patients aged 65 y
preferred the tablet.
56.3 66
Rodenhuis et al28 Scored tablets Score line A total of 24 of 51 negative evaluations of the
score line was reported in patients aged
60 y, mainly because of a combination of
“unequal halves,” “crumbs,” and the tablet
being “difficult to break.” The authors report
that it was not possible to detect any
significant differences between the groups
20-40 y and 60-75 y; however, this was not
proven statistically.
50 N/A
Schiele et al23 Tablets and capsules Size
Surface
Shape
Flavor
74.6% of difficulties related to the dosage form
were due to size; however, acceptable size
was related to the shape. For example,
swallowing difficulties were only slightly
more frequent with oval tablets that had a
length of almost twice the diameter of circular
tablets.
70.5% of difficulties related to the dosage form
were due to surface.
43.5% of difficulties related to the dosage form
were due to shape: hard gelatin capsules, soft
gelatin capsules, and oblong tablets caused a
greater number of problems in comparison to
round and oval tablets.
22.1% of difficulties related to the dosage form
were due to “flavor.”
NB: The older people included in this study
reported fewer swallowing difficulties.
Therefore, they reported fewer preferences
for dosage form characteristics; eg,
approximately 70% of patients without
swallowing difficulties reported no
preferences for the shape of OSDFs.
61.8
(continued on next page)
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Table 2 (continued )
Author Oral Solid Dosage Form Formulation
Characteristic
Key Findings % Patients
Aged 65 y
% Patients
Aged 60 y
Mean
Age, y
Scott et al21 Tablet Taste
Appearance
When exploring the convenience, taste,
appearance, efficacy, and tolerability of the
tablet vs the liquid, the median scores for both
formulations were similar: there were no
significant differences between the 2
formulations. The median global acceptability
score was marginally higher for the tablet
formulation, and the 2 factors that made a
significant contribution toward predicting
global acceptability of the tablet were taste
and appearance.
100 N/A
Vallet et al22 Divisible tablet, coated
tablet, divisible coated
tablet, capsule tablet,
orally disintegrating tablet
Taste
Size
13% of patients (140 patients) required the dose
to be divided as it could not be taken whole.
19% of patients (205 patients) required the use
of food or drink to mask the taste or ease
swallowing.
When exploring medicine “Y” (a psycholeptic
drug), differences in subpopulations of
patients were found, with a higher
acceptability in older patients without
swallowing disorders.
100 86.4
Z.B. Shariff et al. / JAMDA xxx (2020) 1e98taking, removing the dose from the container, and general conve-
nience of taking) found that taste was given the lowest overall
acceptability score.24,27 The unpleasant taste of chewable formula-
tions led to some older people swallowing the tablet whole instead of
chewing,17 and the issue of tastewas also highlighted as a drawback of
dispersible formulations.16,18,30
Appearance
Difficulties distinguishing between different strengths because of
similarities in appearance led to discomfort and clinical deteriora-
tion,17 although sometimes additional markings such as embossments
could help patients differentiate tablets.18 Smaller tablets, including
mini tablets, were difficult to see, especially for older people with
visual impairments.16 Conversely, large tablets can lead to a psycho-
logical block and anxiety before taking medication.18
The type of dosage affected older people’s views on appearance.
Concerns were raised in relation to the appearance of granules, which
were considered the least acceptable “alternative dosage form”
alongside chewable tablets in older people.16 Furthermore, when
comparing tablet and liquid formulations of alendronic acid, therewas
a general trend for the liquid to perform better in terms of appearance,
although this difference was not statistically significant.21
No study was identified that directly investigated the impact of
color on acceptability of oral solid dosage forms within the older
population. A preference survey conducted across ages found color to
have little importance; however, this survey looked primarily at
preference for soft gels.26 A further study on generic substitution that
found external characteristics, including the color of prescription
medication, were less significant than familiarity.29
Discussion
As far as the authors are aware, this is the first systematic review
that has focused on how the characteristics of oral solid dosage forms
affect acceptance and adherence in older people. A preliminary review
to identify studies investigating the appropriateness of medication for
older patients was performed in 2015.31 This preliminary review
looked at the “appropriateness” of all medication, including the route
of administration, drug delivery technology, and frequency of
dosing.31 Both the preliminary review and this one support the urgent
need for further research in this area, with the present review high-
lighting a specific gap in relation to formulation characteristics. Inparticular, 3 key areas were identified by this review that require
further research: the dimensions, palatability, and appearance of oral
solid dosage forms.
The dimensions and palatability of oral solid dosage forms both
affect swallowability, and inappropriate characteristics in either cate-
gory can lead to patients modifying the drug product. Manipulating
dosage forms is a source ofmedication error andharm32 and can lead to
nonadherence.33 Although palatability has been extensively
researched (13 of the 16 included studies explored some aspect of
palatability), furtherwork is needed in thefinal categorydappearance.
This area is especially significant for older people who often use
external characteristics rather than the product label to recognize their
medication.2 Studies in the adult population have found that the use of
multiple medications increases the likelihood of a preference toward
brightly colored tablets,34 and bichromatic dosage forms (thosewith 2
colors) aid rapid identification of the tablet.35 The risk of clinical
deterioration due to similarities in appearancewas supported byonly 1
study in this review,17 highlighting the urgentneed for further research
in this area.
This review is of particular relevance for clinicians working with
older people; 1 in 9 older community-dwelling adults have symptoms
that amount to dysphagia that are likely to be under-reported and
under-recognized.36 Older people with degenerative neurologic con-
ditions such as dementia are at highest risk of dysphagia, as the
cognitive impairment impairs their feeding and swallowing abilities;
however, dysphagia is again often not recognized in these patients.37 As
patients rarely report any difficulties, health care professionals should
proactively enquire about practical problems.15,17,30 Pharmacists in
particular can then use this information to select a dosage form that
causes fewer swallowing difficulties.17,23 Where no suitable oral solid
formulation is available, this may involve collaboration between pro-
fessionals to provide an alternative such as a liquid formulation.
However, there is a greater need to ensure acceptable palatability for
these preparations, and studies have found that liquids are a subopti-
mal alternative to oral solid dosage forms in patients with swallowing
difficulties.38 Health care professionals must therefore work closely
with patients to understand their attitudes toward their treatment and
share decision making on formulation choice with older patients.
This systematic reviewwas conducted by an interdisciplinary team
with expertise in formulation and clinical pharmacy. It used standard
systematic methods to conduct an extensive literature search and
screen relevant studies. The protocol was registered on PROSPERO
prior to screening to reduce potential for bias. However, a key
Z.B. Shariff et al. / JAMDA xxx (2020) 1e9 9limitation is the inherent lack of research in this area. The inclusion
criteria for the study were broad, although only 5 studies were iden-
tified that directly investigated this phenomenon in older peo-
ple.16,19e22 Furthermore, there was a lack of data on ethnicity and on
whether improvements in formulation led to any changes in clinical
outcomes. Five studies were found to be sponsored by or receive
funding from the pharmaceutical industry.21,24e27 Research was
mainly conducted in affluent countries, and the inclusion of English-
language studies only may limit generalizability.
The 3 qualitative studies gave a deeper insight into the challenges
older people facewhenmanagingmedication; however, all focused on
general medication-taking practices. Further qualitative work should
aim to specifically focus on formulation characteristics, looking in
particular at the 3 categories identified from this review. This quali-
tative work should also aim to involve a wider range of people
involved in an older person’s therapy. The systematic review found a
single study that involved General Practitioners, in which their
awareness of swallowing difficulties was assessed;23 however, no
studies were identified that involved formal or informal caregivers.
Eight of the 16 studies included in the review included younger
adults, and the findings highlight preferences for dosage forms that
are easy to swallow.23,25,26,30 It would therefore be valuable for future
research to consider a patient-centric drug product for older people in
comparison to that for the general adult population in order to
highlight any significant differences.
Conclusions and Implications
Adherence to medication is complicated by a number of drug
therapyeassociated factors in older people, namely, the number of
medications, duration of treatment, tablet characteristics, and the
dosage regimen. Although the majority of these are difficult to modify,
ensuring that patients receive an acceptable formulation is a key
intervention that can help reduce nonadherence. Manufacturers must
take into account the practical problems older people may encounter
when considering the dimensions, palatability, and appearance of the
final drug product. These characteristics should be optimized to aid
visual identification and swallowability. Medical providers and phar-
macists have an important role in ensuring that these patient-centric
drug products are prescribed and dispensed appropriately so that
patients receive the most suitable formulation. Future work must
therefore take a multidisciplinary approach so that gaps in perceived
responsibilities in this area can be identified and addressed.
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Supplementary Table 1
PRISMA Checklist
Section/Topic No. Checklist Item Reported on Page No.
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
Abstract
Structured summary 2 Provide a structured summary including, as applicable, background; objectives; data
sources; study eligibility criteria, participants, and interventions; study appraisal and
synthesis methods; results; limitations; conclusions and implications of key findings;
systematic review registration number.
1-2
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known. 3-4
Objectives 4 Provide an explicit statement of questions being addressed with reference to
participants, interventions, comparisons, outcomes, and study design (PICOS).
4
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (eg, Web address),
and, if available, provide registration information including registration number.
5
Eligibility criteria 6 Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics
(eg, years considered, language, publication status) used as criteria for eligibility,
giving rationale.
6 and Supplementary Table 2
Information sources 7 Describe all information sources (eg, databases with dates of coverage, contact with
study authors to identify additional studies) in the search and date last searched.
5 and Supplementary Table 2
Search 8 Present full electronic search strategy for at least 1 database, including any limits used,
such that it could be repeated.
Supplementary Table 2
Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in systematic
review, and, if applicable, included in the meta-analysis).
5-6
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in
duplicate) and any processes for obtaining and confirming data from investigators.
7
Data items 11 List and define all variables for which data were sought (eg, PICOS, funding sources) and
any assumptions and simplifications made.
7, 25-32
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including
specification of whether this was done at the study or outcome level), and how this
information is to be used in any data synthesis.
6
Summary measures 13 State the principal summary measures (eg, risk ratio, difference in means). N/A
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done,
including measures of consistency (eg, I2) for each meta-analysis.
7
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg,
publication bias, selective reporting within studies).
Supplementary Table 4
Additional analyses 16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-
regression), if done, indicating which were prespecified.
N/A
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review,
with reasons for exclusions at each stage, ideally with a flow diagram.
24
Study characteristics 18 For each study, present characteristics for which data were extracted (eg, study size,
PICOS, follow-up period) and provide the citations.
25-32
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment
(see item 12).
Supplementary Table 4
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study (1) simple
summary data for each intervention group and (2) effect estimates and confidence
intervals, ideally with a forest plot.
N/A
Synthesis of results 21 Present results of eachmeta-analysis done, including confidence intervals andmeasures
of consistency.
N/A
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Supplementary Table 4
Additional analysis 23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-
regression [see Item 16]).
N/A
Discussion
Summary of evidence 24 Summarize themain findings including the strength of evidence for eachmain outcome;
consider their relevance to key groups (eg, health care providers, users, and policy
makers).
15-20
Limitations 25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg,
incomplete retrieval of identified research, reporting bias).
19
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and
implications for future research.
15-20
Funding
Funding 27 Describe sources of funding for the systematic review and other support (eg, supply of
data); role of funders for the systematic review.
Title Page
Z.B. Shariff et al. / JAMDA xxx (2020) 1e9 9.e2
Supplementary Table 2
Search Strategy for Systematic Review
MEDLINE Search Strategy (May 2019)
1 1) ((MH¼(Chemistry, Pharmaceutical)) OR TS¼ Pharmaceutical design OR TS¼ dosage form design OR TS¼medic* design OR TS¼ drug product design OR TS¼
pharmaceutical formulation OR TS¼ drug formulation OR TS¼medic* formulation OR TS¼ formulation factors OR TS¼ patient centric OR TS¼ patient-centric
OR TS¼ physical characteristics OR TS¼ physical attributes OR TS¼ appearance OR TS¼ tablet dress OR MH¼(Patient-Centered))
2 2) ((MH¼(Administration, Oral) OR TS¼ “Oral solid” OR TS¼ “oral dosage” OR TS¼ “solid oral” OR TS¼ “solid dosage” OR TS¼ *tablet* OR TS¼ *capsule* OR TS¼
chewable OR TS¼ orodispersible OR TS¼ effervescent OR TS¼ “small tablet$” OR TS¼ “mini tablet$” OR TS¼ “hard capsule$” OR TS¼ “soft capsule$” OR TS¼
“fixed dose combination$”))
3 3) (((MH¼(Patient Compliance OR Medication Adherence OR Treatment Refusal OR Patient Preference))))
4 4) TS¼ elderly OR TS¼ aged OR TS¼ older OR TS¼ geriatric OR TS¼ "over 60"
5 1 AND 2 AND 3 AND 4
Cochrane Library Search Strategy (May 2019)
1 ("pharmaceutical design" or "dosage form design" or "medic* design" or "drug product design" or "pharmaceutical formulation" or "drug formulation" or
"medic* formulation" or "formulation factors" or "patient centric" or "patient-centric" or "physical characteristics" or "physical attributes" or appearance or
"tablet dress") in Title Abstract Keyword
2 ("Oral solid" or "oral dosage" or "solid oral" or "solid dosage" or *tablet* or *capsule* or chewable or orodispersible or effervescent or "small tablet" or "mini
tablet" or "hard capsule" or "soft capsule" or "fixed dose combination") in Title Abstract Keyword
3 (appropriate* OR acceptab* OR usab* OR swallow* OR dysphagia OR prefer* OR persist* OR adhere* OR complian* OR nonadhere* OR non-adhere* OR
noncomplian* OR non-complian* OR concordan*) in Title Abstract Keyword
4 (elderly OR aged OR older OR geriatric OR "over 60")
5 1 AND 2 AND 3 AND 4
Scopus (May 2019)
1 TITLE-ABS-KEY ("Pharmaceutical design" OR "dosage form design" OR "medic* design" OR "drug product design" OR "pharmaceutical formulation" OR "drug
formulation" OR "medic* formulation" OR "formulation factors" OR "patient centric" OR "physical characteristics" OR "physical attributes" OR appearance OR
"tablet dress")
2 TITLE-ABS-KEY ("Oral solid" OR "oral dosage" OR "solid oral" OR "solid dosage" OR *tablet* OR *capsule* OR chewable OR orodispersible OR effervescent OR
"small tablet" OR "mini tablet" OR "hard capsule" OR "soft capsule" OR "fixed dose combination")
3 TITLE-ABS-KEY (appropriate* OR acceptab* OR usab* OR swallow* OR dysphagia OR prefer* OR persist* OR adhere* OR complian* OR nonadhere* OR non-
adhere* OR noncomplian* OR non-complian* OR concordan*)
4 TITLE-ABS-KEY (elderly OR aged OR older OR geriatric OR "over 60")
5 1 AND 2 AND 3 AND 4
Web of Science (May 2019)
1 TS¼ “Pharmaceutical design”OR TS¼ “dosage form design”OR TS¼ “medic* design”OR TS¼ “drug product design”OR TS¼ “pharmaceutical formulation”OR TS¼
“drug formulation” OR TS¼ “medic* formulation” OR TS¼ “formulation factors” OR TS¼ “patient centric” OR TS¼ “patient-centric” OR TS¼ “physical
characteristics” OR TS¼ “physical attributes” OR TS¼ appearance OR TS¼ “tablet dress”
2 TS¼ “Oral solid” OR TS¼ “oral dosage” OR TS¼ “solid oral” OR TS¼ “solid dosage” OR TS¼ *tablet* OR TS¼ *capsule* OR TS¼ chewable OR TS¼ orodispersible OR
TS¼ effervescent OR TS¼ “small tablet$” OR TS¼ “mini tablet$” OR TS¼ “hard capsule$” OR TS¼ “soft capsule$” OR TS¼ “fixed dose combination$”
3 TS¼ Appropriate* OR TS¼ acceptab* OR TS¼ usab* OR TS¼ swallow* OR TS¼ dysphagia OR TS¼ prefer* OR TS¼ persist* OR TS¼ adhere* OR TS¼ complian* OR
TS¼ nonadhere* OR TS¼ non-adhere* OR TS¼ noncomplian* OR TS¼ non-complian* OR TS¼ concordan*
4 TS¼ elderly OR TS¼ aged OR TS¼ older OR TS¼ geriatric OR TS¼ "over 60"
5 1 AND 2 AND 3 AND 4
Google Scholar Search Strategy (June 2018)
1 “Oral Solid”
2 Adherence
3 “Older”
4 1 AND 2 AND 3
Other Sources: 1. BASE (May 2019)“oral solid” “adherence” “older” 2. EThOS (May 2019)“oral” AND “adherence” AND “older people” 3. OpenGrey (May 2019)(“oral”) AND
(adherence) AND (older OR elderly OR geriatric OR “over 60") 4. WoS Conference Proceedings: Conference Proceedings Citation Index- Science (CPCI-S) –1990-present (May
2019)TOPIC: (oral AND (older OR elderly OR geriatric) AND adherence).
“Over 60s”was defined as the included population for this review in order to ensure all relevant studies were identified. The scoping search found a number of studies that had
potentially relevant data for this systematic review but that defined or categorized the older person as “over 60.”
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Supplementary Table 3
Reasons for Exclusion
No. Study Name Reason for Exclusion
1 Aleksovski A, Dreu R, Gasperlin M, Planinsek O. Mini-tablets: A
contemporary system for oral drug delivery in targeted patient groups.
Expert Opin Drug Deliv 2015;12:65-84.
Review from which no additional references were found
2 Andersen O, Zweidorff OK, Hjelde T, Rodland EA. Problems when
swallowing tablets. A questionnaire study from general practice. Tidsskr
Nor Lageforen 1995;115:947-949.
Only available in German
3 Argoff CE, Kopecky EA. Patients with chronic pain and dysphagia (CPD):
Unmet medical needs and pharmacologic treatment options. Curr Med
Res Opin 2014;30:2543-2559.
Review from which no additional references were found
4 Bayer AJ, Day JJ, Finucane P, Pathy MSJ. Bioavailability and acceptability of a
dispersible formulation of levodopa-benserazide in parkinsonian patients
with and without dysphagia. J Clin Pharm Ther 1988;13:191-194.
Does not explore the formulation characteristics that affected preference for
each formulation
5 Bhosle M, Benner JS, Dekoven M, Shelton J. Difficult to swallow: Patient
preferences for alternative valproate pharmaceutical formulations. Patient
Prefer Adherence 2009;3:161-171.
1.2% (5 participants) aged 65 y and no data provided that would added to
results
6 Bitter I, Treuer T, Dilbaz N, et al. Patients’ preference for olanzapine
orodispersible tablet compared with conventional oral tablet in a
multinational, randomized, crossover study. World J Biol Psychiatry
2010;11:894-903.
Participants aged 18-65 y; however, unable to extract data for older people
7 Blanco MA, Prieto M, Mearin F, et al; El Grupo Del Estudio LAN/41/01.
Evaluation of preferences in patients with gastroesophageal reflux disease
and dysphagia concerning treatment with lansoprazole orally
disintegrating tablets. Gastroenterol Hepatol 2009;32:542-548.
Only available in Spanish
8 Boateng J. Drug delivery innovations to address global health challenges for
pediatric and geriatric populations (through improvements in patient
compliance). J Pharm Sci 2017;106:3188-3198.
Commentary from which no additional references were found
9 Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug
Deliv 2007;4:37-45.
Review from which no additional references were found
10 Buckalew LW, Ross S. Medication property effects on expectations of action.
Drug Dev Res 1991;23:101-108.
Unable to extract data for older people on preferences for formulation
characteristics. Focus is more on perceived indications based on color.
11 Casian T, Bogdan C, Tarta D, et al. Assessment of oral formulation-dependent
characteristics of orodispersible tablets using texture profiles and
multivariate data analysis. J Pharm Biomed Anal 2018;152:47-56.
Participants aged 22-57 y
12 Channer KS, Virjee JP. The effect of formulation on oesophageal transit. J
Pharm Pharmacol 1985;37:126-129.
Unable to extract data for older people because of differences in mean age
between the groups given differing formulations; focus on esophageal
transit rather than patient acceptability.
13 Chu XY, Gao CH, Ge C, Gao CS. Progress in researches of patient-centric
individualized formulation approaches. Chin J New Drugs 2018;27:409-
416.
Only available in Chinese
14 Danileviciute V, Adomaitiene V, Sveikata A, et al. Compliance in psychiatry:
Results of a survey of depressed patients using orally disintegrating tablet.
Medicina (Kaunas) 2006;42:1006-1012.
Only available in Lithuanian
15 De Argila CM, Ponce J, Marquez E, et al. Acceptability of lansoprazole orally
disintegrating tablets in patients with gastro-oesophageal reflux disease:
ACEPTO study. Clin Drug Invest 2007;27:765-770.
Unable to extract data for older people
16 Denneboom W, Dautzenberg MGH, Grol R, De Smet PAGM. User-related
pharmaceutical care problems and factors affecting them: The importance
of clinical relevance. J Clin Pharm Ther 2005;30:215-223.
Does not explore formulation as defined for the review
17 Derosa G, Romano D, Bianchi L, et al. Metformin powder formulation
compared to metformin tablets on glycemic control and on treatment
satisfaction in subjects with type 2 diabetes mellitus. J Clin Pharmacol
2015;55:409-414.
Does not explore the formulation characteristics that affected preference for
each formulation
18 Desai RJ, Sarpatwari A, Dejene S, et al. Differences in rates of switchbacks
after switching from branded to authorized generic and branded to
generic drug products: Cohort study. BMJ (Clin Res Ed) 2018;361:k1180.
Does not explore the formulation characteristics that impacted the rates of
switchbacks in sufficient detail for the review
19 Drumond N, Van Riet-Nales DA, Karapinar-Carkit F, Stegemann S. Patients’
appropriateness, acceptability, usability and preferences for
pharmaceutical preparations: Results from a literature review on clinical
evidence. Int J Pharm 2017;521:294-305.
Review from which no additional references were found
20 Faisal W, Farag F, Abdellatif AAH, Abbas A. Taste masking approaches for
medicines. Curr Drug Deliv 2018;15:167-185.
Review from which no additional references were found
21 Forough AS, Lau ET, Steadman KJ, et al. A spoonful of sugar helps the
medicine go down? A review of strategies for making pills easier to
swallow. Patient Prefer Adherence 2018;12:1337.
Reviewdadditional reference (Schiele et al, 2013) retrieved
22 Goyanes A, Scarpa M, Kamlow M, et al. Patient acceptability of 3D printed
medicines. Int J Pharm 2017;530:71-78.
Participants aged 18-45 y
23 Grady H, Kukulka MJ, Ono T, Nudurupati SV. Evaluation of physical
characteristics of dexlansoprazole orally disintegrating tablets. Pharm
Technol 2018;42:30-37.
Unable to extract data for older people
24 Hanning SM, Lopez FL, Wong ICK, et al. Patient centric formulations for
paediatrics and geriatrics: Similarities and differences. Int J Pharm
2016;512:355-359.
Review from which no additional references were found
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25 Hey H, Jørgensen F, Sørensen K, et al. Oesophageal transit of six commonly
used tablets and capsules. BMJ 1982;285:1717-1719.
Focus on esophageal transit of medication rather than patient adherence or
acceptance
26 Howell EH, Senapati A, Hsich E, Gorodeski EZ. Medication self-management
skills and cognitive impairment in older adults hospitalized for heart
failure: A cross-sectional study. SAGE Open Med
2017;5:2050312117700301.
Does not explore formulation as defined for the review; focus more on the
impact of cognitive impairment on health literacy
27 Ibrahim IR, Izham MM, Al-Haddad M. Consumer preferences and
perceptions towards the use of colored oral solid dosage forms in
Baghdad. Arch Pharm Pract 2010;1:15.
Unable to extract data for older people
28 Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of
osteoporosis: Review of a novel, easy to swallow formulation. Clin Interv
Aging 2013;8:681-688.
Review from which no additional references were found
29 Jamison J, Sutton S, Mant J, De Simoni A. Barriers and facilitators to
adherence to secondary stroke prevention medications after stroke:
Analysis of survivors and caregivers views from an online stroke forum.
BMJ Open 2017;7:e016814.
Does not explore formulation in older people as defined for the review
30 Kakuda TN, Berckmans C, De Smedt G, et al. Single-dose pharmacokinetics of
pediatric and adult formulations of etravirine and swallowability of the
200-mg tablet: results from three phase 1 studies. Int J Clin Pharmacol
Ther 2013;51:725-737.
Unable to extract data for older people; mean age 49 y for swallowability
study
31 Kelly J, D’Cruz G, Wright D. A qualitative study of the problems surrounding
medicine administration to patients with dysphagia. Dysphagia
2009;24:49-56.
Does not explore formulation as defined for the review; focus more on
health care professionals’ administration of medication
32 Kraemer S, Chartier F, Augendre-Ferrante B, et al. Effectiveness of two
formulations of oral olanzapine in patients with schizophrenia or bipolar
disorder in a natural setting: Results from a 1-year European
observational study. Hum Psychopharmacol 2012;27:284-294.
Unable to extract data for older people
33 Lam PW, Lum CM, Leung MF. Drug non-adherence and associated risk
factors among Chinese geriatric patients in Hong Kong. Hong Kong Med J
2007;13:284-292.
Does not explore formulation factors that may lead to nonadherence as
defined for the review
34 Lenahan JL, McCarthy DM, Davis TC, et al. A drug by any other name:
Patients’ ability to identify medication regimens and its association with
adherence and health outcomes. J Health Commun 2013;18:31-39.
Does not explore formulation factors which may impact adherence or
acceptance as defined for the review
35 Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design
to improve acceptability of medicines: Similarities and differences in
paediatric and geriatric populations. Drugs 2014;74:1871-1889.
Review from which no additional references were found
36 Liu Y, Li P, Qian R, et al. A novel and discriminative method of in vitro
disintegration time for preparation and optimization of taste-masked
orally disintegrating tablets of carbinoxamine maleate. Drug Dev Ind
Pharm 2018;44:1317-1327.
In vivo testing carried out in 6 healthy volunteers; unable to extract data for
older people
37 Lopez FL, Bowles A, Gul MO, et al. Effect of formulation variables on oral
grittiness and preferences of multiparticulate formulations in adult
volunteers. Eur J Pharm Sci 2016;92:156-162.
Participants aged 20-25 y
38 Lumbreras B, Lopez-Pintor E. Impact of changes in pill appearance in the
adherence to angiotensin receptor blockers and in the blood pressure
levels: A retrospective cohort study. BMJ Open 2017;7.
Does not explore the formulation characteristics in detail that may lead to a
change in adherence
39 Mackenzie-Smith L, Marchi P, Thorne H, et al. Patient preference and
physician perceptions of patient preference for oral pharmaceutical
formulations: Results from a real-life survey. Inflamm Intest Dis
2018;3:43-51.
Unable to extract data for older people
40 Marquez-Contreras E, Gil V, Lopez J, et al. Pharmacological compliance and
acceptability of lansoprazole orally disintegrating tablets in primary care.
Curr Med Res Opin 2008;24:569-576.
Unable to extract preferences for formulation characteristics for older
people
41 Matuszewski K, Kapusnik-Uner J, Man M, et al. Variation in generic drug
manufacturers’ product characteristics. Pharm Ther 2018;43:485-504.
Does not measure impact of formulation on adherence or acceptance as
defined for the review
42 McGillicuddy A, Kelly M, Sweeney C, et al. Modification of oral dosage forms
for the older adult: An Irish prevalence study. Int J Pharm 2016;510:386-
393.
Does not explore the formulation characteristics that led to swallowing
difficulties and the resulting modifications
43 McGillicuddy A, Kelly M, Crean AM, SAHM LJ. Understanding the knowledge,
attitudes and beliefs of community-dwelling older adults and their carers
about the modification of oral medicines: A qualitative interview study to
inform healthcare professional practice. Res Social Adm Pharm 2019.
Conference Abstract (published paper not yet available)
44 Mehuys E, Dupond L, Petrovic M, et al. Medication management among
home-dwelling older patients with chronic diseases: Possible roles for
community pharmacists. J Nutr Health Aging 2012;16:721-726.
Does not explore the formulation characteristics that cause the practical
problems when taking medicines
45 Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial
comparing budesonide formulations and dosages for short-term
treatment of eosinophilic oesophagitis. Gut 2016;65:390.
Does not explore the characteristics of each formulation that led to the
patient’s preferred preference
46 Miller CA. Safe medication practices: Administering medications to elders
who have difficulty swallowing. Geriatr Nurs 2003;24:378-379.
Review from which no additional references were found
47 Ogata I, Yamasaki K, Tsuruda A, et al. Some problems for dosage form based
on questionnaire surveying compliance in patients taking tamsulosin
hydrochloride. Yakugaku zasshi: Journal of the Pharmaceutical Society of
Japan 2008;128:291-297.
Only available in Japanese
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48 Papanastasiou A, Kalantzi L. Innovation in formulation development for
older people. J Aging Sci 2018;6:2.
Review from which no additional references were found
49 Park C, Meghani NM, Amin HH, et al. Patient-centered drug delivery and its
potential applications for unmet medical needs. Ther Deliv 2017;8:775-
790.
Review from which no additional references were found
50 Patel MX, De Zoysa N, Bernadt M, David A. Depot and oral antipsychotics:
Patient preferences and attitudes are not the same thing. J
Psychopharmacol 2009;23:789-796.
Does not explore formulation characteristics of the oral antipsychotics as
defined for the review
51 Patsalos PN, Russell-Jones D, Finnerty G, et al. The efficacy and tolerability of
chewable carbamazepine compared to conventional carbamazepine in
patients with epilepsy. Epilepsy Res 1990;5:235-239.
Does not explore the formulation characteristics that led to a preference for
either formulation
52 Pepic I, Lovric J. Challenges in patient-centric oral dosage form designdThe
example of sumamed. Medicus 2018;27:171-175.
Only available in Croatian
53 Pereira BC, Isreb A, Forbes RT, et al. “Temporary Plasticiser”: A novel solution
to fabricate 3D printed patient-centred cardiovascular “Polypill”
architectures. Eur J Pharm Biopharm 2019;135:94-103.
Unable to extract data for older people (only in vitro testing conducted)
54 Perkins AC, Wilson CG, Frier M, et al. Esophageal transit of risedronate
cellulose-coated tablet and gelatin capsule formulations. Int J Pharm
1999;186:169-175.
Does not measure patient adherence or acceptance, rather looks at
esophageal transit
55 Quinn HL, Hughes CM, Donnelly RF. Novel methods of drug administration
for the treatment and care of older patients. Int J Pharm 2016;512:366-
373.
Review from which no additional references were found
56 Reilly TM. Medication management in the elderly: Major opportunity for
advances in drug delivery & formulation technologies. Drug Deliv Technol
2009;9:52-57.
Review from which no additional references were found
57 Roger A, Fortea J, Mora S, Artés M. Ebastine fast-dissolving tablets versus
regular tablets: Acceptability and preference in patients with allergic
rhinitis. Expert Rev Clin Pharmacol 2008;1:381-389.
Sample excludes older people
58 Roger Reig A, Plazas FernandezMJ, Galvan Cervera J, et al. Acceptance survey
of a fast dissolving tablet pharmaceutical formulation in allergic patients.
Satisfaction and expectancies. Allergol Immunopathol 2006;34:107-112.
Unable to extract data for older people
59 Roman B. Patients’ attitudes towards generic substitution of oral atypical
antipsychotics: A questionnaire-based survey in a hypothetical pharmacy
setting. CNS Drugs 2009;23:693-701.
Unable to extract data for older people
60 Roose SP. Compliance: The impact of adverse events and tolerability on the
physician’s treatment decisions. Eur Neuropsychopharmacol
2003;13:S85-92.
Review from which no additional references were found
61 Sajatovic M, Thompson TR, Nanry K, et al. Prospective, open-label trial
measuring satisfaction and convenience of two formulations of
lamotrigine in subjects with mood disorders. Patient Prefer Adherence
2013;7:411-417.
Unable to extract data for older people
62 Satyanarayana DA, Kulkarni PK, Shivakumar HG. Gels and jellies as a dosage
form for dysphagia patients: A review. Curr Drug Therapy 2011;6:79-86.
Review from which no additional references were found
63 Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system
for famotidine. J Clin Pharmacol 1995;35:362-367.
Unable to extract data for older people on the formulation characteristics of
the wafer and tablet that led to patient preference
64 Serrano-Castro PJ, Mauri-Llerda JA, Garcia A, et al. Treatment adherence
with levetiracetam: a non-interventionist retrospective observation-
based study. Rev Neurol 2016;62:481-486.
Only available in Spanish
65 Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and
elderly. Eur J Pharm Sci 2015;75:2-9.
Review from which no additional references were found
66 Stegemann S, GoschM, Breitkreutz J. Swallowing dysfunction and dysphagia
is an unrecognized challenge for oral drug therapy. Int J Pharm
2012;430:197-206.
Review from which no additional references were found
67 Stegemann S, Ternik R. L, Onder G, et al. Defining patient centric
pharmaceutical drug product design. AAPS J 2016;18:1047-1055.
White paper; no additional references found
68 Tahaineh L,WazaifyM. Difficulties in swallowing oral medications in Jordan.
Int J Clin Pharm 2017:39:373-379.
Unable to extract data for older people
69 Tao D, Wang T, Wang T, Qu X. Influence of drug colour on perceived drug
effects and efficacy. Ergonomics 2018;61:284-294.
Unable to extract data for older people
70 Thirion O, Neggazi N, Almaqdissi A, et al. “Patient centric design”:
Contribution to medicine safety. STP Pharma Pratiq 2014;24:347-351.
Review article from which no additional references were found
71 Trenfield SJ, Awad A, Goyanes A, et al. 3D printing pharmaceuticals: Drug
development to frontline care. Trends Pharmacol Sci 2018;39:440-451.
Review from which no additional references were found
72 Trivedi MR, Patel HH, Dave RH. A Review on tablet scoring: Background,
history and current regulatory considerations. Br J Pharm Res 2017;20.
Review from which no additional references were found
73 Van Riet-Nales DA, Hussain N, Sundberg KAE, et al. Regulatory incentives to
ensure better medicines for older people: From ICH E7 to the EMA
reflection paper on quality aspects. Int J Pharm 2016;512:343-351.
Review from which no additional references were found
74 Walsh J, Ranmal S. R, Ernest TB, Liu F. Patient acceptability, safety and access:
A balancing act for selecting age-appropriate oral dosage forms for
paediatric and geriatric populations. Int J Pharm 2018;536:547-562.
Review from which no additional references were found
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75 Wight LJ, Vandenburg MJ, Potter CE, Freeth CJ. A large scale comparative
study in general practice with nitroglycerin spray and tablet formulations
in elderly patients with angina pectoris. European J Clin Pharmacol
1992:42:341-342.
Does not explore the characteristics of each formulation that led to the
patient’s preferred preference
76 Williams B, Shaw A, Durrant R, et al. Patient perspectives on multiple
medications versus combined pills: a qualitative study. QJM 2005;98:885-
893.
Does not explore the formulation characteristics in detail that impact
acceptability as defined for the review
77 Yanze MF, Duru C, Jacob M, et al. Rapid therapeutic response onset of a new
pharmaceutical form of chloroquine phosphate 300 mg: Effervescent
tablets. Tropic Med Int Health 2001;6:196-201.
Participants aged between 19-51 y
78 Zanardi R, Colombo L, Marcheggiani E, et al. Paroxetine drops versus
paroxetine tablets: Evaluation of compliance in a six-month study. Riv
Psichiatr 2013;48:261-267.
Unable to extract data for older people
79 Zgraggen L, Fare PB, Lava SAG, et al. Palatability of crushed SS-blockers,
converting enzyme inhibitors and thiazides. J Clin Pharm Ther
2012;37:544-546.
Participants aged between 24-50
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Supplementary Table 4
Quality Appraisal of Included Studies Using the MMAT*
First Author 1. Qualitative Studiesy Pharma Sponsored or Funding||
1.1. Is the Qualitative Approach
Appropriate to Answer the
Research Question?
1.2. Are the Qualitative Data
Collection Methods Adequate
to Address the Research
Question?
1.3. Are the Findings
Adequately Derived From the
Data?
1.4. Is the Interpretation of
Results Sufficiently
Substantiated by Data?
1.5. Is There Coherence
Between Qualitative Data
Sources, Collection, Analysis
and Interpretation?
Kelly18 Yes Yes Yes Yes Yes No
Notenboom20 Yes Yes Yes Yes Yes No
Notenboom21 Yes Yes Yes Yes Yes No
First Author 2. Randomized Controlled Trialsx Pharma Sponsored or Funding
2.1. Is Randomization
Appropriately Performed?
2.2. Are the Groups Comparable
at Baseline?
2.3. Are There Complete
Outcome Data?
2.4. Are Outcome Assessors
Blinded to the Intervention
Provided?
2.5 Did the Participants Adhere
to the Assigned Intervention?
den Uyl27 Yes Can’t tell Yes No Yes Yes
Hofmanová28 Yes Can’t tell Yes Yes Yes Yes
Philips22 Can’t tell Can’t tell No Can’t tell Yes No
Rees23 Can’t tell Yes Yes Yes Yes No
Reginster30 Yes Can’t tell No No No Yes
First Author 3. Quantitative Nonrandomized Studies Pharma Sponsored or Funding
3.1. Are the Participants
Representative of the Target
Population?
Are Measurements Appropriate
Regarding Both the Outcome
and Intervention (or
Exposure)?
3.3. Are There Complete
Outcome Data?
3.4. Are the Confounders
Accounted for in the Design and
Analysis?
3.5. During the Study Period, Is
the Intervention Administered
(or Exposure Occurred) as
Intended?
Scott24 Yes Yes No Yes Yes Yes
Vallet25 Yes Yes Yes Yes Can’t tell No
First Author 4. Quantitative Descriptive Studiesz Pharma Sponsored or Funding
4.1. Is the Sampling Strategy
Relevant to Address the
Research Question?
4.2. Is the Sample
Representative of the Target
Population?
4.3. Are the Measurements
Appropriate?
4.4. Is the Risk of Nonresponse
Bias Low?
4.5. Is the Statistical Analysis
Appropriate to Answer the
Research Question?
Heikkilä32 Yes Yes Yes Yes Yes No
Jones29 No No Can’t tell Can’t tell No Yes
Liu19 Yes Yes Yes Can’t tell Yes No
Marquis33 Yes Yes Can’t tell No Yes No
Rodenhuis31 Can’t tell Can’t tell Can’t tell Can’t tell No No
Schiele26 Yes Yes Can’t tell Can’t tell Yes No
Notes to Quality Appraisal: *All included studies had clear research questions and collected data that addressed the research question. yThe 3 qualitative studies (18, 20, 21) scored highly, with all using semistructured interviews
to collect data from which quotes were extracted and used to illustrate the interpretation of the results. zThe quality of the 6 quantitative descriptive studies (19, 26, 29, 31-33) varied, with 2 studies scoring very low because of
unclear sampling strategies, a nonrepresentative sample, uncertainty over the validity of the survey used and few details reported in relation to the analysis of data. xAll 5 randomized crossover studies (22, 23, 28, 30, 49)
investigated the formulation of oral solid dosage forms directly; however, the quality of these studies again varied, with 1 study scoring very low because of insufficient details in the reporting of the study to enable the quality to
be assessed. jjFive studies (24, 27-30) received financial support from or were sponsored by the pharmaceutical industry, 3 of which were randomized crossover studies (27, 28, 30) and 2 of which studied calcium and vitamin D
Formulations (27, 30). The quality of these again varied, with 1 study in particular having scoring very low because of irrelevant sampling strategies and an unrepresentative sample (29).
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